Showing 7381-7390 of 21432 results for "".
- Zongertinib Demonstrates Promising Efficacy in Patients with HER2-Mutant Non-Small Cell Lung Cancerhttps://reachmd.com/news/zongertinib-demonstrates-promising-efficacy-in-patients-with-her2-mutant-non-small-cell-lung-cancer/2468153/by International Association for the Study of Lung Cancer
- Studies Provide First Evidence That Breastfeeding After Breast Cancer Is Safehttps://reachmd.com/news/studies-provide-first-evidence-that-breastfeeding-after-breast-cancer-is-safe/2468145/Two international studies presented at the ESMO Congress 2024 show no increase in recurrence or new breast cancers in women who breastfeed after being treated for breast cancer. Results provide the first evidence that breastfeeding after breast cancer is feasible and safe
- UMass Amherst Researcher to Use Wearable Sleep Trackers, AI to Predict Early Signs of Alzheimer’shttps://reachmd.com/news/umass-amherst-researcher-to-use-wearable-sleep-trackers-ai-to-predict-early-signs-of-alzheimers/2468142/The National Institutes of Health has awarded Joyita Dutta, professor of biomedical engineering at the University of Massachusetts Amherst, $3.9 million over five years to study if wearable sleep trackers can predict blo
- Pediatricians Highlight Role of ACIP During COVID-19 Pandemichttps://reachmd.com/news/pediatricians-highlight-role-of-acip-during-covid-19-pandemic/2468144/BYLINE: Myra Wright Key takeaways:Virtual meeting format allowed emergency meetings to be quickly scheduled and enabled members of the public to attend.Efforts should always be made to include diverse populations in
- How the Scars of Demolished Brain Tumors Seed Relapsehttps://reachmd.com/news/how-the-scars-of-demolished-brain-tumors-seed-relapse/2468136/SEPTEMBER 9, 2024, NEW YORK – A Ludwig Cancer Research study has discovered that recurrent tumors of the aggressive brain cancer glioblastoma multiforme (GBM) grow out of the fibrous scars of malignant predecessors destroyed by interventions such as radiotherapy, surge
- U of U Health Part of National Study Comparing Fentanyl, Ketamine in Treating Trauma Painhttps://reachmd.com/news/u-of-u-health-part-of-national-study-comparing-fentanyl-ketamine-in-treating-trauma-pain/2468029/SALT LAKE CITY (KUTV) — Fentanyl and ketamine are going head to head in a new trial for trauma pain relief.The study will examine which drug provides better pain relief with fewer side effects for injured patients before they reach the hospital.The study, know
- Zynex Obtains FDA Clearance for New Pain Management Devicehttps://reachmd.com/news/zynex-obtains-fda-clearance-for-new-pain-management-device/2468118/ENGLEWOOD, Colo., Sept. 3, 2024 /PRNewswire/ -- Zynex Inc. (NASDAQ: ZYXI),
- New Spanish Language Stroke Prevention Website Aims to Remove Barriers to Equitable Healthhttps://reachmd.com/news/new-spanish-language-stroke-prevention-website-aims-to-remove-barriers-to-equitable-health/2468128/DALLAS, September 9, 2024 — While stroke is the fifth-leading overall cause of death in the United States, it disproportionately impacts Hispanic people. It is the third leading cause of death among Hispanic women and the fourth leading cause of
- Evernorth Announces Another Step Forward in Lowering Drug Prices by Making a Stelara Biosimilar Available at $0 Out of Pocket for Patients Early Next Yearhttps://reachmd.com/news/evernorth-announces-another-step-forward-in-lowering-drug-prices-by-making-a-stelara-biosimilar-available-at-0-out-of-pocket-for-patients-early-next-year/2468119/BLOOMFIELD, Conn., Sept. 5, 2024 /PRNewswire/ -- Evernorth Health Services announced that it plans to have a Stelara biosimilar available for $0 out of pocket for eligible patients of its specialty pharmacy, Accredo, beginning in early 2025. The interchangeable biosimilar will be produced for Eve
- Penn Research Uncovers Key Biomarker for Diagnosing Sarcoidosishttps://reachmd.com/news/penn-research-uncovers-key-biomarker-for-diagnosing-sarcoidosis/2468124/Sarcoidosis is a rare systemic disease that afflicts an estimated 200,000 people in the US, more often people who are Black and more women than men, particularly when it causes chronic skin disease. It's nicknamed "the great mimicker," because it